Literature DB >> 9652762

Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry.

K L Marsh1, J M Varley.   

Abstract

Progression through G1 phase of the eukaryotic cell cycle is tightly controlled by cyclin-dependent kinases (CDK). These proteins form part of a regulatory pathway including the cyclin-dependent kinase inhibitor (CKI) p16, D-type cyclins and the product of the retinoblastoma gene pRb. Aberration of any one of these components may lead to uncontrolled proliferation contributing to neoplasia. Three of these proteins, cyclin D1, pRb and p16, were analysed by immunohistochemistry on archival paraffin sections to determine whether expression patterns were different in preinvasive ductal carcinoma in situ (DCIS) and invasive breast tumours relative to normal. Genetic analysis of the gene encoding cyclin D1 (CCND1) was also carried out, using an intragenic restriction fragment-length polymorphism (RFLP) to assess possible allelic imbalance. A majority of the tumours studied (approximately 90%) showed abnormalities in expression of at least one of these proteins. Overexpression of cyclin D1 was found in approximately 49% cases, reduced expression of p16 in approximately 46% and reduced expression of pRb in approximately 37%. Allelic imbalance of cyclin D1 was found in approximately 57% cases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652762      PMCID: PMC2150197          DOI: 10.1038/bjc.1998.240

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  41 in total

1.  Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.

Authors:  Y Sonoda; T Yoshimoto; T Sekiya
Journal:  Oncogene       Date:  1995-11-16       Impact factor: 9.867

2.  Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival.

Authors:  E M Berns; A de Klein; W L van Putten; I L van Staveren; A Bootsma; J G Klijn; J A Foekens
Journal:  Int J Cancer       Date:  1995-04-21       Impact factor: 7.396

3.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.

Authors:  K Ueki; Y Ono; J W Henson; J T Efird; A von Deimling; D N Louis
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

4.  Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines.

Authors:  J He; J J Olson; C D James
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

5.  Cyclin D1 provides a link between development and oncogenesis in the retina and breast.

Authors:  P Sicinski; J L Donaher; S B Parker; T Li; A Fazeli; H Gardner; S Z Haslam; R T Bronson; S J Elledge; R A Weinberg
Journal:  Cell       Date:  1995-08-25       Impact factor: 41.582

6.  Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.

Authors:  A J Brenner; C M Aldaz
Journal:  Cancer Res       Date:  1995-07-01       Impact factor: 12.701

7.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.

Authors:  J A Reed; F Loganzo; C R Shea; G J Walker; J F Flores; J M Glendening; J K Bogdany; M J Shiel; F G Haluska; J W Fountain
Journal:  Cancer Res       Date:  1995-07-01       Impact factor: 12.701

8.  Alternate splicing produces a novel cyclin D1 transcript.

Authors:  D C Betticher; N Thatcher; H J Altermatt; P Hoban; W D Ryder; J Heighway
Journal:  Oncogene       Date:  1995-09-07       Impact factor: 9.867

9.  Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types.

Authors:  J Lukas; J Bartkova; M Welcker; O W Petersen; G Peters; M Strauss; J Bartek
Journal:  Oncogene       Date:  1995-06-01       Impact factor: 9.867

10.  Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions.

Authors:  D Weinstat-Saslow; M J Merino; R E Manrow; J A Lawrence; R F Bluth; K D Wittenbel; J F Simpson; D L Page; P S Steeg
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

View more
  8 in total

Review 1.  Cell cycle genes in a mouse mammary hyperplasia model.

Authors:  Thenaa K Said; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

2.  Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.

Authors:  V G Gorgoulis; E N Koutroumbi; A Kotsinas; P Zacharatos; C Markopoulos; L Giannikos; V Kyriakou; Z Voulgaris; I Gogas; C Kittas
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

3.  Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population.

Authors:  Zhangyong Hu; Zhipeng Zhou; Guolian Xiong; Yali Wang; Yi Lai; Lan Deng; Jinliang Yang
Journal:  Tumour Biol       Date:  2014-02-26

4.  Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population.

Authors:  Kaur Satinder; Sobti Ranbir Chander; Kaur Pushpinder; Gupta Indu; Jain Veena
Journal:  Mol Cell Biochem       Date:  2008-06-12       Impact factor: 3.396

5.  Validation of transgenic models of breast cancer: ductal carcinoma in situ (DCIS) and Brca1-mutation-related breast cancer.

Authors:  M S Frech; L P Jones; P A Furth
Journal:  Breast Cancer Online       Date:  2005-08-01

6.  Rb localization and phosphorylation kinetics correlate with the cellular phenotype of cultured breast adenocarcinoma cells.

Authors:  Jeannine Botos; Rola Barhoumi; Robert Burghardt; Deborah T Kochevar
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-04       Impact factor: 2.416

7.  Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment response.

Authors:  Blanca Murillo-Ortiz; Horacio Astudillo-De la Vega; Sebastian Castillo-Medina; J M Malacara; Luis Benitez-Bribiesca
Journal:  BMC Cancer       Date:  2006-08-15       Impact factor: 4.430

8.  Network and data integration for biomarker signature discovery via network smoothed T-statistics.

Authors:  Yupeng Cun; Holger Fröhlich
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.